Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

NCT07753720 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Erectile Dysfunction
Tadalafil

Interventions

DRUG: Tadalafil; Current on-demand PDE5 inhibitor
DRUG: Tadalafil 5 mg

Sponsor

Al-Azhar University